B. Riley keeps Buy rating on Altimmune after Q4 results, pipeline updates

B. Riley noted that Altimmune provided several pipeline updates along with reporting Q4 results, notably pertaining to pemvidutide execution through mid-stage clinical development. The Phase 2 MOMENTUM non-diabetes obesity study remains on track to report 160-subject 24-week interim analysis in the second half of March and final 48-week readout in Q4 and a new Phase 2 biopsy-proven NASH study is guided for mid-2023 initiation, said the analyst, noting in regards to the latter that the firm is "encouraged by the pace of execution to capitalize on the best-in-indication liver fat reduction" noted in the company’s recently concluded Phase Ib NAFLD study. B. Riley reiterates a Buy rating and $26 price target on Altimmune shares.